Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 5
2002 15
2003 50
2004 57
2005 76
2006 105
2007 109
2008 152
2009 113
2010 111
2011 133
2012 151
2013 153
2014 177
2015 142
2016 134
2017 112
2018 103
2019 83
2020 83
2021 104
2022 74
2023 47
2024 48
2025 53
2026 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,165 results

Results by year

Filters applied: . Clear all
Page 1
Atazanavir.
Goldsmith DR, Perry CM. Goldsmith DR, et al. Drugs. 2003;63(16):1679-93; discussion 1694-5. doi: 10.2165/00003495-200363160-00003. Drugs. 2003. PMID: 12904086 Review.
Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir has a pharmacokinetic profile that allows for once-daily oral administration. ...
Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir …
Atazanavir.
Orrick JJ, Steinhart CR. Orrick JJ, et al. Ann Pharmacother. 2004 Oct;38(10):1664-74. doi: 10.1345/aph.1D394. Epub 2004 Sep 7. Ann Pharmacother. 2004. PMID: 15353575 Review.
In clinical trials in antiretroviral (ARV)-naive patients, atazanavir had efficacy similar to that of efavirenz or nelfinavir. In ARV-experienced patients, atazanavir was inferior to lopinavir/ritonavir unless atazanavir was coadministered with low-dose riton …
In clinical trials in antiretroviral (ARV)-naive patients, atazanavir had efficacy similar to that of efavirenz or nelfinavir. In ARV …
Atazanavir sulphate.
Raja A, Lebbos J, Kirkpatrick P. Raja A, et al. Nat Rev Drug Discov. 2003 Nov;2(11):857-8. doi: 10.1038/nrd1232. Nat Rev Drug Discov. 2003. PMID: 14702957 No abstract available.
Atazanavir Resensitizes Candida auris to Azoles.
Elgammal Y, Salama EA, Seleem MN. Elgammal Y, et al. Antimicrob Agents Chemother. 2023 May 17;67(5):e0163122. doi: 10.1128/aac.01631-22. Epub 2023 Apr 24. Antimicrob Agents Chemother. 2023. PMID: 37092991 Free PMC article.
Candida auris represents an urgent health threat. Here, we identified atazanavir as a potent drug capable of resensitizing C. auris clinical isolates to the activity of azole antifungals. Atazanavir was able to significantly inhibit the efflux pumps, glucose transpo …
Candida auris represents an urgent health threat. Here, we identified atazanavir as a potent drug capable of resensitizing C. auris c …
Atazanavir urolithiasis.
Chang HR, Pella PM. Chang HR, et al. N Engl J Med. 2006 Nov 16;355(20):2158-9. doi: 10.1056/NEJMc061892. N Engl J Med. 2006. PMID: 17108352 No abstract available.
Atazanavir crystal nephropathy.
Izzedine H, M'rad MB, Bardier A, Daudon M, Salmon D. Izzedine H, et al. AIDS. 2007 Nov 12;21(17):2357-8. doi: 10.1097/QAD.0b013e3282f17503. AIDS. 2007. PMID: 18090291 No abstract available.
Atazanavir-associated menorrhagia.
Paparizos VA, Kourkounti S, Leuow K, Kyriakis KP, Botsi C, Katsambas AD. Paparizos VA, et al. Int J STD AIDS. 2007 Sep;18(9):651-2. doi: 10.1258/095646207781568637. Int J STD AIDS. 2007. PMID: 17785018 No abstract available.
Efavirenz urolithiasis.
Izzedine H, Valantin MA, Daudon M, Mohand HA, Caby F, Katlama C. Izzedine H, et al. AIDS. 2007 Sep 12;21(14):1992. doi: 10.1097/QAD.0b013e3282ef792f. AIDS. 2007. PMID: 17721118 No abstract available.
Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV.
Kengo A, Resendiz-Galvan JE, Najjemba L, Mugerwa H, De Nicolò A, D'Avolio A, Atoyebi S, Wiesner L, Svensson EM, Waitt C, Denti P. Kengo A, et al. Br J Clin Pharmacol. 2025 Dec;91(12):3471-3481. doi: 10.1002/bcp.70195. Epub 2025 Aug 12. Br J Clin Pharmacol. 2025. PMID: 40796001 Free PMC article. Clinical Trial.
A two-compartment model with an effect-compartment effectively described atazanavir concentrations in plasma and PBMC. Rifampicin increased atazanavir clearance threefold, while decreasing its bioavailability and absorption rate. Doubling dosing frequency of ATV/r l …
A two-compartment model with an effect-compartment effectively described atazanavir concentrations in plasma and PBMC. Rifampicin inc …
2,165 results